BR112013017367A2 - polipeptídeo de alfacarpo, sequência de ácido nucléico, composição farmacêutica e método para a produção de pelo menos um polipeptídeo de alfacorpo - Google Patents
polipeptídeo de alfacarpo, sequência de ácido nucléico, composição farmacêutica e método para a produção de pelo menos um polipeptídeo de alfacorpoInfo
- Publication number
- BR112013017367A2 BR112013017367A2 BR112013017367A BR112013017367A BR112013017367A2 BR 112013017367 A2 BR112013017367 A2 BR 112013017367A2 BR 112013017367 A BR112013017367 A BR 112013017367A BR 112013017367 A BR112013017367 A BR 112013017367A BR 112013017367 A2 BR112013017367 A2 BR 112013017367A2
- Authority
- BR
- Brazil
- Prior art keywords
- polypeptide
- alphabodies
- polypeptides
- caracarp
- carabin
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 9
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 9
- 150000007523 nucleic acids Chemical group 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2011050138 | 2011-01-06 | ||
PCT/EP2012/050193 WO2012093172A1 (en) | 2011-01-06 | 2012-01-06 | Alphabodies specifically binding to cytokines or growth factors and/or cytokine or growth factor receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013017367A2 true BR112013017367A2 (pt) | 2016-11-22 |
Family
ID=44242740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013017367A BR112013017367A2 (pt) | 2011-01-06 | 2012-01-06 | polipeptídeo de alfacarpo, sequência de ácido nucléico, composição farmacêutica e método para a produção de pelo menos um polipeptídeo de alfacorpo |
Country Status (9)
Country | Link |
---|---|
US (1) | US20140057830A1 (pt) |
JP (1) | JP2014504869A (pt) |
CN (1) | CN103339148A (pt) |
AU (1) | AU2012204846B2 (pt) |
BR (1) | BR112013017367A2 (pt) |
CA (1) | CA2821646A1 (pt) |
DK (1) | DK2661447T3 (pt) |
IN (1) | IN2013MN01394A (pt) |
WO (1) | WO2012093172A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3763740A1 (en) | 2011-01-26 | 2021-01-13 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
US20140363434A1 (en) * | 2012-01-06 | 2014-12-11 | Complix Nv | Binding agents to intracellular target molecules |
EP4063391A1 (en) | 2012-07-25 | 2022-09-28 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
WO2014064080A1 (en) | 2012-10-22 | 2014-05-01 | Complix Nv | Polypeptides specifically binding to il-23 |
CA2888930C (en) | 2012-10-22 | 2020-10-20 | Complix Nv | Polypeptides capable of cellular internalization |
EP3145543A4 (en) | 2014-05-23 | 2017-12-13 | Celldex Therapeutics, Inc. | Treatment of eosinophil or mast cell related disorders |
WO2017102835A1 (en) * | 2015-12-14 | 2017-06-22 | Complix Nv | Binding molecule comprising an alphabody-polypeptide and an antibody |
CN113315431B (zh) * | 2021-04-22 | 2023-07-28 | 湖南工业大学 | 基于等价输入干扰系统的pmsm失磁故障控制方法、电机 |
CN114544812B (zh) * | 2022-02-18 | 2023-06-30 | 复旦大学附属中山医院 | 一种代谢组合式标志物在诊断哮喘中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101323643B (zh) * | 2007-06-15 | 2010-12-01 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白 |
EP2161278B1 (en) * | 2008-09-08 | 2012-05-23 | Complix N.V. | Single-chain coiled coil scaffold |
WO2010066740A1 (en) * | 2008-12-08 | 2010-06-17 | Complix Nv | Single-chain antiparallel coiled coil proteins |
EP2661446B1 (en) * | 2011-01-06 | 2015-09-30 | Complix SA | Alphabody libraries and methods for producing the same |
-
2012
- 2012-01-06 WO PCT/EP2012/050193 patent/WO2012093172A1/en active Application Filing
- 2012-01-06 DK DK12702771.2T patent/DK2661447T3/en active
- 2012-01-06 CN CN2012800046860A patent/CN103339148A/zh active Pending
- 2012-01-06 AU AU2012204846A patent/AU2012204846B2/en not_active Ceased
- 2012-01-06 BR BR112013017367A patent/BR112013017367A2/pt not_active IP Right Cessation
- 2012-01-06 US US13/994,107 patent/US20140057830A1/en not_active Abandoned
- 2012-01-06 JP JP2013547867A patent/JP2014504869A/ja active Pending
- 2012-01-06 CA CA2821646A patent/CA2821646A1/en not_active Abandoned
- 2012-01-06 IN IN1394MUN2013 patent/IN2013MN01394A/en unknown
Also Published As
Publication number | Publication date |
---|---|
DK2661447T3 (en) | 2015-11-02 |
AU2012204846B2 (en) | 2016-09-08 |
US20140057830A1 (en) | 2014-02-27 |
IN2013MN01394A (pt) | 2015-06-12 |
AU2012204846A1 (en) | 2013-07-04 |
CA2821646A1 (en) | 2012-07-12 |
CN103339148A (zh) | 2013-10-02 |
WO2012093172A1 (en) | 2012-07-12 |
JP2014504869A (ja) | 2014-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013017367A2 (pt) | polipeptídeo de alfacarpo, sequência de ácido nucléico, composição farmacêutica e método para a produção de pelo menos um polipeptídeo de alfacorpo | |
AR113177A2 (es) | Polipéptidos que tienen actividad de lisozima y polinucleótidos que los codifican | |
AR088322A1 (es) | Anticuerpos anti-htra1 y metodos de uso | |
BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
CL2017002082A1 (es) | Nuevas proteínas especificas para pioverdina y pioquelina | |
BR112015029788A2 (pt) | hetero-multímero, construto de anticorpo isolado, ácido nucleico, célula hospedeira, método para preparar o hetero-multímero, composição farmacêutica, método para tratar uma doença, uso do hetero-multímero, uso de uma quantia terapêutica do hetero-multímero e método para reduzir a função efetora de um construto de anticorpo | |
EA201490815A1 (ru) | Составы этанерцепта, стабилизированные с помощью аминокислот | |
BR112014026308A8 (pt) | meios de cultura celular, seu método de cultura, polipeptídeo, seu método de produção e seu uso, composições farmacêutica, e kit | |
BR112016027585A2 (pt) | construções de anticorpo multiespecíficas | |
CL2014002166A1 (es) | Proteína de fusión de factor viii recombinante que comprende al polipéptido recombinante extendido xten; composición farmacéutica que la comprende; ácido nucleico que la codifica; vector; célula huésped; método de producción; y uso para tratar una coagulopatía, tal como hemofilia. | |
BR112012029588A2 (pt) | materiais biológicas relacionados a her3. | |
CO6612271A2 (es) | Anticuerpos anti-cd40 | |
MX2015008446A (es) | Composiciones de proteinas de union multivalentes. | |
MX2021010668A (es) | Proteinas de fusion de citoquinas. | |
CL2015000757A1 (es) | Una proteina | |
SG10201906859PA (en) | Novel proteins specific for angiogenesis | |
BR112016002753A2 (pt) | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos | |
AR073088A1 (es) | Anticuerpos anti-il-13 obtenidos mediante ingenieria composiciones metodos y usos | |
PH12014501912A1 (en) | Cx3cr1-binding polypeptides | |
BR112014029174A2 (pt) | composição de ativador geopolimérico, composição geopolimérica e método para a preparação de uma composição geopolimérica | |
BR112013003722A2 (pt) | produtos para cuidado e métodos de uso e fabricação dos mesmos | |
BR112014002817A2 (pt) | Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62 | |
EA201290565A1 (ru) | Получение белка гемагглютинин-нейраминидазы в микроводорослях | |
EA201400850A1 (ru) | Альфа-амилаза | |
BR112015021993A2 (pt) | composições de cultura celular com antioxidantes e métodos para produção de polipeptídeo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2547 DE 29-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |